South Africa

2017 – 2018

Wendy Stevens, Souleymane Mboup, Ilesh Jani (and their teams)

  1. Dorman SE, Schumacher SG, Alland D, Nabeta P, Armstrong DT, King B, Hall SL, Chakravorty S, Cirillo DM, Tukvadze N, Bablishvili N, Stevens WScott L, Rodrigues C, Kazi MI, Joloba M, Nakiyingi L, Nicol MP, Ghebrekristos Y, Anyango I, Murithi W, Dietze R, Lyrio Peres R, Skrahina A, Auchynka V, Chopra KK, Hanif M, Liu X, Yuan X, Boehme CC, Ellner JJ, Denkinger CM. (2018) Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. The Lancet Infectious diseases 18(1):76-84. Published online 30 November 2017. DOI: 10.1016/S1473-3099(17)30691-6. PMID: 29198911. Impact Factor: 19.864.
  2. Kroeze S, Ondoa P, Kityo CM, Siwale M, Akanmu S, Wellington M, de Jager M, Ive P, Mandaliya K, Stevens W, Boender TS, de Pundert ME, Sigaloff KCE, Reiss P, Wit FWNM, Rinke de Wit TF, Hamers RL. (2018). Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan Africa. AIDS 32(8): 1043-1051. DOI: 10.1097/QAD.0000000000001801. PMID: 29547445. Impact Factor: 5.003.
  3. Coetzee J, Hunt G, Jaffer M, Otwombe K, Scott L, Bongwe A, Ledwaba J, Molema S, Jewkes R, Gray GE. (2017) HIV-1 viraemia and drug resistance amongst female sex workers in Soweto, South Africa: A cross sectional study. PLoS One 12(12):e0188606. DOI: 10.1371/journal.pone.0188606. PMID: 29244809. Impact Factor: 2.806.
  4. Hanifa Y, Fielding KL, Chihota VN, Adonis L, Charalambous S, Foster N, Karstaedt A, McCarthy K, Nicol MP, Ndlovu NT, Sinanovic E, Sahid F, Stevens W, Vassall A, Churchyard GJ, Grant AD. A clinical scoring system to prioritise investigation for tuberculosis amoung adults attending HIV clinics in South Africa. PLoS One 12:8 (2017): e0181519. Published online 3 August 2017.DOI: 10.1371/journal.pone.0181519. PMID: 28771504. Impact Factor: 2.806.
  5. Scott LDavid ANoble LNduna M, Da Silva P, Black A, Venter F, Stevens W. Performance of the Abbott RealTime MTB and MTB RIF/INH Assays in a Setting of High Tuberculosis and HIV Coinfection in South Africa. Journal of Clinical Microbiology 55:8 (2017): 2491-2501. Published online 7 June 2017.  DOI: 10.1128/JCM.00289-17. PMID: 28592547. Impact Factor: 3.712.
  6. Stevens W, Gous NM, MacLeod WB, Long LC, Variava E, Martinson NA, Sanne I, Osih R, Scott LE. Multidisciplinary Point of Care testing in South African primary healthcare clinics accelerates HIV ART initiation but does not alter retention in care. JAIDS 76:1 (2017) 65-73. Published online 23 May 2017. DOI: 10.1097/QAI.0000000000001456. PMID: 28542080. Impact Factor: 3.935.
  7. Chikaonda T, Nguluwe N, Barnett B, Gakhale RH, Krysiak R, Thengolose I, Rosenberg NE, Stanley C, Mpunga J, Hoffman IF, Hosseinipour M, Scott LStevens W. Performance of Xpert® MTB/RIF among tuberculosis outpatients in Lilongwe, Malawi. African Journal of Laboratory Medicine 6:2 (2017). Published online 31 March 2017. DOI: 10.4102/ajlm.v6i2.464. Impact Factor (2015): 1.16.
  8. Chikaonda T, Ketseoglou I, Nguluwe N, Krysiak R, Thengolose I, Nyakwawa F, Rosenberg NE, Stanley C, Mpunga J, Hoffman IF, Papathanasopoulos MA, Hosseinipour M, Scott LStevens W.Molecular characterisation of rifampicin resistant Mycobacterium tuberculosis strains from Malawi. African Journal of Laboratory Medicine 6:2 (2017). Published online 31 March 2017. DOI: 10.4102/ajlm.v6i2.463. Impact Factor (2015): 1.16.
  9. Scott LE, Kestens L, Pattanapanyasat K, Sukapirom K, Stevens W. Choosing a new CD4 technology: can statistical method comparison tools influence the decision? Cytometry Part B 92B (2017) 465-475. Published online 10 March 2017. DOI: 10.1002/cyto.b.21522. PMID: 28296063. Impact Factor: 2.474
  10. Smith H, Smith J, Glencross D, Naseem C, Coetzee L, Carmona S, Stevens W. Siting of HIV/AIDS diagnostic equipment in South Africa: a case study in locational analysis. Accepted to International Transactions in Operational Research 25 (2018) 319-336. Published online 8 February 2017. DOI: 10.1111/itor.12366. Impact Factor: 1.745.
  11. Jacobson KR, Barnard M, Kleinman MB, Streicher EM, Ragan EJ, White LF, Shapira O, Dolby T, Simpson J, Scott LStevens W, van Helden PD, Van Rie A, Warren R. Implications of failure to routinely diagnose resistance to second-line drugs in patients with rifampicin-resistant tuberculosis on Xpert MTB/RIF: a multisite observational study. Clinical Infectious Diseases. Published online: 12 February 2017. DOI: 10.1093/cid/cix128. PMID: 28199520. Impact Factor: 8.216.
  12. Venter WD, Ford N, Vitoria M, Stevens W. Diagnosis and monitoring of HIV programmes to support treatment initiation and follow up and improve programme quality. Current Opinion in HIV and AIDS. 12:2 (2017) 117-122. DOI: 10.1097/COH.0000000000000354. PMID: 28134712. Impact Factor: 4.05.
  13. Scott L, da Silva P, Boehme CC, Stevens W, Gilpin CM. Diagnosis of opportunistic infections: HIV co-infections – tuberculosis. Current Opinion in HIV and AIDS 12:2 (2017) 129-138. DOI: 10.1097/COH.0000000000000345. PMID: 28059955. Impact Factor: 4.05.
  14. Cox H, Dickson-Hall L, Ndjeka N, van’t Hoog A, Grant A, Cobelens F, Stevens W, Nicol M. Delays to treatment and the treatment gap for drug-resistant tuberculosis in South Africa: a national retrospective cohort study assessing the impact of Xpert implementation. PLoS Medicine 14:2 (2017) e1002238. DOI: 10.1371/journal.pmed.1002238. PMID: 28222095. Impact Factor: 11.862.
  15. Maskew M, Bor J, Hendrickson C, MacLeod W, Bärnighausen T, Pillay D, Sanne I, Carmona S, Stevens W, Fox M. Imputing HIV treatment start dates from routine laboratory data in South Africa: a validation study. BMC Health Services Research 17:41 (2017). DOI: 10.1186/s12913-016-1940-2. PMID: 28095905. Impact Factor: 1.827
  16. Cobb B, Simon CO, Stramer SL, Body B, Mitchell PS, Reisch N, Stevens W, Carmona S, Katz L, Will S, Liesenfeld O. The cobas® 6800/8800 System: a new era of automation in molecular diagnostics. Expert Review of Molecular Diagnostics 17:2 (2017) 167-80. DOI: 10.1080/14737159.2017.1275962. PMID: 28043179. Impact Factor: 1.
  17. Peter T, Ellenberger D, Kim AA, Boeras D, Messele T, Roberts T, Stevens WJani I, Abimiku A, Ford N, Katz Z, Nkengasong JN. Early antiretroviral therapy initiation: access and equity of viral load testing for HIV treatment monitoring. Review. Lancet Infectious Diseases 17:1 (2017) e26-e29. Published online 20 October 2016. DOI: 10.1016/S1473-3099(16)30212-2. PMID: 27773596. Impact Factor: 19.864.
  18. Steegen K, Bronze M, Papthanasopoulos M, van Zyl G, Goedhals D, Variava E, MacLeod W, Sanne I, Stevens W, Carmona S. HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa. Journal of Antimicrobial Chemotherapy 72:1 (2017) 210-9. DOI: 1031093/jac/dkw358. PMID: 27659733. Impact Factor: 5.071.
  19. Stevens WSScott LNoble L, Gous N, Dheda K. Impact of the GeneXpert MTB/RIF technology on tuberculosis control. Microbiology Spectrum 5:1 (2017) TBTB2-0040-2016. DOI: 10.1128/microbiolspec.TBTB2-0040-2016. PMID: 28155817. No impact factor available (book chapter).


  1. Essajee S, Bhairavabhotla R, Penazzato M, Kiragu K, Jani I, Carmona S, Rewari B, Kiyaga C, Nkengasong J, Peter T. Scale-up of Early Infant HIV Diagnosis and Improving Access to Pediatric HIV Care in Global Plan Countries: Past and Future Perspectives. J Acquir Immune Defic Syndr. 2017 May 1;75 Suppl 1:S51-S58. doi: 10.1097/QAI.0000000000001319. PubMed PMID: 28398997.
  2. Meggi B, Bollinger T, Mabunda N, Vubil A, Tobaiwa O, Quevedo JI, Loquiha O, Vojnov L, Peter TF, Jani IV. Point-Of-Care p24 Infant Testing for HIV May Increase Patient Identification despite Low Sensitivity. PLoS One. 2017 Jan 6;12(1):e0169497. doi: 10.1371/journal.pone.0169497. eCollection 2017. PubMed PMID: 28060886; PubMed Central PMCID: PMC5218410.
  3. Sitoe N, Macamo R, Meggi B, Tobaiwa O, Loquiha O, Bollinger T, Vojnov L, Jani I. Performance Evaluation of the MyT4 Technology for Determining ART Eligibility. PLoS One. 2016 Oct 25;11(10):e0165163. doi: 10.1371/journal.pone.0165163. eCollection 2016. PubMed PMID: 27780216; PubMed Central PMCID: PMC5079624.
  4. Peter T, Ellenberger D, Kim AA, Boeras D, Messele T, Roberts T, Stevens W, Jani I, Abimiku A, Ford N, Katz Z, Nkengasong JN. Early antiretroviral therapy initiation: access and equity of viral load testing for HIV treatment monitoring. Lancet Infect Dis. 2017 Jan;17(1):e26-e29. doi: 10.1016/S1473-3099(16)30212-2. Epub 2016 Oct 20. Review. PubMed PMID: 27773596.
  5. Manhiça I, Bhatt N, Ismael N, Nhavene E, Grinsztejn B, Veloso V, Maueia C, Augusto O, Jani I, Gudo ES. First Report of Prevalence of HTLV-1 Among HIV-1/2-Infected Children in Mozambique. J Acquir Immune Defic Syndr. 2017 Feb 1;74(2):e54-e56. doi: 10.1097/QAI.0000000000001194. PubMed PMID: 2775368